CJC-1295 / Ipamorelin Blend
$110.00
$5.50 per mg
A GHRH analogue and a ghrelin-receptor agonist combined 1:1.
Buy more, save more
Applies to any mix of sizes of this compound. Discount shows in your cart.
- Batch RP-CIB-2610, lab report sent on request
- Sealed vial, discreet unbranded packaging
- Order now and it ships on Monday
For in-vitro laboratory research only. Not for human or veterinary use.
Composition
| Component | Share | In 20 mg vial |
|---|---|---|
| CJC-1295 (no DAC) | 50% | 10 mg |
| Ipamorelin | 50% | 10 mg |
Each component comes from a released, independently tested batch. Component batch numbers are listed on the blend’s report.
Specifications
| Also known as | Mod GRF (1-29) 10 mg + Ipamorelin 10 mg |
|---|---|
| Purity specification | ≥98.0% per component (HPLC) |
| Form | Lyophilized powder, 3 mL glass vial |
| Storage | −20 °C, sealed, protected from light |
Batch history
Every batch we have released for this compound, with the report for each. Older reports stay available so you can compare lots.
-
RP-CIB-2610 Shipping now
Request report
Research overview
Combines modified GRF (1-29), which acts at the GHRH receptor, with ipamorelin, a selective GHS-R1a agonist. The pairing is used to study how the two pituitary signalling pathways interact.
Each component is drawn from a released, batch-tested lot before blending, and the component batch numbers are listed on the blend’s report.
